128 related articles for article (PubMed ID: 32205017)
1. Antitumor activity of ipatasertib combined with chemotherapy: results from a phase Ib study in solid tumors.
Isakoff SJ; Tabernero J; Molife LR; Soria JC; Cervantes A; Vogelzang NJ; Patel MR; Hussain M; Baron A; Argilés G; Conkling PR; Sampath D; Maslyar D; Patel P; Chan W; Gendreau S; Musib L; Xu N; Ma H; Lin K; Bendell J
Ann Oncol; 2020 May; 31(5):626-633. PubMed ID: 32205017
[TBL] [Abstract][Full Text] [Related]
2. A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors.
Shapiro GI; LoRusso P; Cho DC; Musib L; Yan Y; Wongchenko M; Chang I; Patel P; Chan IT; Sanabria-Bohorquez S; Meng RD; Bendell JC
Invest New Drugs; 2021 Feb; 39(1):163-174. PubMed ID: 32737717
[TBL] [Abstract][Full Text] [Related]
3. A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer.
Bang YJ; Kang YK; Ng M; Chung HC; Wainberg ZA; Gendreau S; Chan WY; Xu N; Maslyar D; Meng R; Chau I; Ajani JA
Eur J Cancer; 2019 Feb; 108():17-24. PubMed ID: 30592991
[TBL] [Abstract][Full Text] [Related]
4. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Kim SB; Dent R; Im SA; Espié M; Blau S; Tan AR; Isakoff SJ; Oliveira M; Saura C; Wongchenko MJ; Kapp AV; Chan WY; Singel SM; Maslyar DJ; Baselga J;
Lancet Oncol; 2017 Oct; 18(10):1360-1372. PubMed ID: 28800861
[TBL] [Abstract][Full Text] [Related]
5. Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer.
Yuan Y; Yost SE; Cui Y; Ruel C; Murga M; Tang A; Martinez N; Schmolze D; Waisman J; Patel N; Vora L; Tumyan L; Bozoghlanian M; Stewart D; Frankel PH
Oncologist; 2023 Jul; 28(7):e498-e507. PubMed ID: 37023705
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of ipatasertib as a single agent and in combination with abiraterone plus prednisolone in Japanese patients with advanced solid tumors.
Doi T; Fujiwara Y; Matsubara N; Tomomatsu J; Iwasa S; Tanaka A; Endo-Tsukude C; Nakagawa S; Takahashi S
Cancer Chemother Pharmacol; 2019 Aug; 84(2):393-404. PubMed ID: 31227862
[TBL] [Abstract][Full Text] [Related]
7. FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer.
Oliveira M; Saura C; Nuciforo P; Calvo I; Andersen J; Passos-Coelho JL; Gil Gil M; Bermejo B; Patt DA; Ciruelos E; de la Peña L; Xu N; Wongchenko M; Shi Z; Singel SM; Isakoff SJ
Ann Oncol; 2019 Aug; 30(8):1289-1297. PubMed ID: 31147675
[TBL] [Abstract][Full Text] [Related]
8. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
Friedlander M; Meniawy T; Markman B; Mileshkin L; Harnett P; Millward M; Lundy J; Freimund A; Norris C; Mu S; Wu J; Paton V; Gao B
Lancet Oncol; 2019 Sep; 20(9):1306-1315. PubMed ID: 31378459
[TBL] [Abstract][Full Text] [Related]
9. Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer.
Dent R; Oliveira M; Isakoff SJ; Im SA; Espié M; Blau S; Tan AR; Saura C; Wongchenko MJ; Xu N; Bradley D; Reilly SJ; Mani A; Kim SB;
Breast Cancer Res Treat; 2021 Sep; 189(2):377-386. PubMed ID: 34264439
[TBL] [Abstract][Full Text] [Related]
10. A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer.
Abramson VG; Oliveira M; Cervantes A; Wildiers H; Patel MR; Bauer TM; Bedard PL; Becerra C; Richey S; Wei MC; Reyner E; Bond J; Cui N; Wilson TR; Moore HM; Saura C; Krop IE
Breast Cancer Res Treat; 2019 Nov; 178(1):121-133. PubMed ID: 31368034
[TBL] [Abstract][Full Text] [Related]
11. Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial.
Patnaik A; Yap TA; Chung HC; de Miguel MJ; Bang YJ; Lin CC; Su WC; Italiano A; Chow KH; Szpurka AM; Yu D; Zhao Y; Carlsen M; Schmidt S; Vangerow B; Gandhi L; Xu X; Bendell J
Clin Cancer Res; 2021 Mar; 27(5):1267-1277. PubMed ID: 33229456
[TBL] [Abstract][Full Text] [Related]
12. A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer.
Pook D; Geynisman DM; Carles J; de Braud F; Joshua AM; Pérez-Gracia JL; Llácer Pérez C; Shin SJ; Fang B; Barve M; Maruzzo M; Bracarda S; Kim M; Kerloeguen Y; Gallo JD; Maund SL; Harris A; Huang KC; Poon V; Sutaria DS; Gurney H
Clin Cancer Res; 2023 Sep; 29(17):3292-3300. PubMed ID: 37339186
[TBL] [Abstract][Full Text] [Related]
13. A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors.
Saura C; Roda D; Roselló S; Oliveira M; Macarulla T; Pérez-Fidalgo JA; Morales-Barrera R; Sanchis-García JM; Musib L; Budha N; Zhu J; Nannini M; Chan WY; Sanabria Bohórquez SM; Meng RD; Lin K; Yan Y; Patel P; Baselga J; Tabernero J; Cervantes A
Cancer Discov; 2017 Jan; 7(1):102-113. PubMed ID: 27872130
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers.
Chon HS; Kang S; Lee JK; Apte SM; Shahzad MM; Williams-Elson I; Wenham RM
BMC Cancer; 2017 Jun; 17(1):407. PubMed ID: 28595616
[TBL] [Abstract][Full Text] [Related]
15. Phase 1b dose escalation study of erlotinib in combination with infusional 5-Fluorouracil, leucovorin, and oxaliplatin in patients with advanced solid tumors.
Hanauske AR; Cassidy J; Sastre J; Bolling C; Jones RJ; Rakhit A; Fettner S; Brennscheidt U; Feyereislova A; Díaz-Rubio E
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):523-31. PubMed ID: 17255274
[TBL] [Abstract][Full Text] [Related]
16. A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors.
LoRusso PM; Infante JR; Kim KB; Burris HA; Curt G; Emeribe U; Clemett D; Tomkinson HK; Cohen RB
BMC Cancer; 2017 Mar; 17(1):173. PubMed ID: 28264648
[TBL] [Abstract][Full Text] [Related]
17. A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors.
Vermorken JB; Rottey S; Ehrnrooth E; Pelling K; Lahogue A; Wind S; Machiels JP
Ann Oncol; 2013 May; 24(5):1392-400. PubMed ID: 23293114
[TBL] [Abstract][Full Text] [Related]
18. Population Pharmacokinetics of Ipatasertib and Its Metabolite in Cancer Patients.
Yoshida K; Wilkins J; Winkler J; Wade JR; Kotani N; Wang N; Sane R; Chanu P
J Clin Pharmacol; 2021 Dec; 61(12):1579-1591. PubMed ID: 34273118
[TBL] [Abstract][Full Text] [Related]
19. A phase I trial to determine the safety, pharmacokinetics, and pharmacodynamics of intercalated BMS-690514 with paclitaxel/carboplatin (PC) in advanced or metastatic solid malignancies.
Chow LQ; Jonker DI; Dy GK; Nicholas G; Fortin C; Patricia D; Adjei AA; Belani CP; Gupta A; Park JS; Zhang S; Sbar EI; Laurie SA
Cancer Chemother Pharmacol; 2013 May; 71(5):1273-85. PubMed ID: 23468081
[TBL] [Abstract][Full Text] [Related]
20. A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors.
McRee AJ; Sanoff HK; Carlson C; Ivanova A; O'Neil BH
Invest New Drugs; 2015 Dec; 33(6):1225-31. PubMed ID: 26490655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
